Nilo Therapeutics has launched with a $101 million Series A to develop drugs that modulate neural circuits to restore immune homeostasis, and has appointed Kim Seth, Ph.D., as CEO. The round, led by The Column Group, DCVC Bio, and Lux Capital with participation from the Gates Foundation and Alexandria Venture Investments, will fund new labs in New York, team expansion, and advancement of preclinical programs. Founded by Charles Zuker, Ruslan Medzhitov, and Steve Liberles, the company aims to target central “master regulator” brain–body circuits—specifically vagal pathways implicated in systemic inflammation—rather than peripheral cytokines or immune cells. Seth joins chief scientific officer Laurens Kruidenier, Ph.D., to guide the transition out of stealth.
The strategic bet is clear: if central circuit modulation can recalibrate immune networks upstream of peripheral inflammation, Nilo could redefine immunomodulation beyond conventional immunosuppression. The unanswered question is whether a CNS-acting medicine can reliably and safely deliver multi-pathway immune control across diseases—and whether regulators, HCPs, and payers will accept neural-circuit pharmacology as a durable alternative to the familiar biologics and JAK/TYK2 inhibitors.
The timing matters. Autoimmune markets are booming, but differentiation is narrowing, and payer tolerance for step edits, duplicative MOAs, and long-term safety risk is tightening. A therapy that coordinates immune pathways centrally could reduce resistance, broaden impact across indications, and compress the polypharmacy seen in complex autoimmune care. Yet the translational bar is high: mechanistic evidence must link target engagement in the brainstem to reproducible downstream immune signatures and clinical benefit. Progress in bioelectronic medicine and vagus nerve stimulation has hinted at the neuro-immune axis’s potential, but drug-based, CNS-penetrant approaches will need novel biomarkers and endpoints to move from plausibility to practice.
For patients and clinicians, success would recalibrate treatment sequencing in conditions like IBD, RA, psoriasis, and lupus—potentially shifting from chronic peripheral suppression toward circuit-informed control that may pair with, or displace, existing standards. Medical Affairs teams will need to bridge immunology and neuroscience, educating rheumatologists, gastroenterologists, and neurologists on autonomic markers, cytokine network dynamics, and safety monitoring for centrally active agents. For payers, the promise of broad, multi-indication utility will invite scrutiny on durability, steroid-sparing effects, infection risk, and total cost offsets; outcomes-based contracts and cross-indication evidence packages could be decisive.
Commercially, indication selection and proof-of-mechanism strategy are pivotal. Early programs that can demonstrate rapid, quantifiable immune recalibration—using autonomic measures, inflammatory transcriptomics, and validated clinical disease activity scores—will set the tone for valuation and partnering. Real-world evidence will be essential to validate adherence, flare prevention, healthcare utilization impact, and neuropsychiatric safety in routine care. On the BD front, large-cap immunology players facing lifecycle pressure on anti-cytokines and TYK2 portfolios will watch closely; a positive human signal could catalyze platform deals or co-development, especially if Nilo’s approach scales across immune-mediated diseases.
This raise, in a selective 2025 funding environment, signals investor conviction that central immunoregulation could be the next pillar in inflammation. The next 18–24 months will hinge on Nilo’s ability to show target engagement in humans, establish a robust biomarker playbook linking the brain–immune axis to clinical outcomes, and pick indications where circuit-level modulation can deliver clear, payer-relevant advantages. If those pieces align, the competitive question shifts from whether the strategy works to who will build the category and own the care pathways that connect the brain to the immune system.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
